In this post, I link to and excerpt from Lecanemab: Appropriate Use Recommendations [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. The Journal of Prevention of Alzheimer’s Disease volume 10, pages362–377 (2023).
The above resource was cited by
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients.
Ramanan VK, Day GS.
Mol Neurodegener. 2023 Jun 28;18(1):42. doi: 10.1186/s13024-023-00637-0.
PMID: 37381015 Free PMC article.
In addition to the above resource, please see and review:
- Commentary
Published: 17 May 2023
Clinical Efficacy in Individual Patients Treated with Lecanemab
Serge Gauthier, J. Therriault & P. Rosa-Neto
The Journal of Prevention of Alzheimer’s Disease volume 10, pages378–379 (2023) - Editorial
Published: 17 April 2023
Implications of Emerging Uses of Genetic Testing for Alzheimer’s Disease
Drew Blasco & J. S. Roberts
The Journal of Prevention of Alzheimer’s Disease volume 10, pages359–361 (2023)
All that follows is from from Lecanemab: Appropriate Use Recommendations [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. The Journal of Prevention of Alzheimer’s Disease volume 10, pages362–377 (2023).
Coming soon.
